Navigation Links
Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
Date:11/13/2008

STOCKHOLM, November 13 /PRNewswire/ -- Karolinska Development AB, a Swedish investment company using a unique, highly cost effective model to commercialize internationally renowned life science announced today the appointment of Dr. Carl Harald Janson as investment manager.

"Carl Harald is an outstanding addition to our management team," stated Conny Bogentoft, Chief Executive Officer of Karolinska Development. "His extensive experience within the medical, pharmaceutical and investment arenas will provide an invaluable perspective for our future growth". His former activities have included work as Medical Adviser for Clinical Research and Director of Immunology for Preclinical R&D at Astra Arcus AB, Senior Financial Analyst at Hagstromer & Qviberg Fondkommission AB and Danske Securities, Danske Bank in Stockholm. He moved into fund management with companies including Carnegie Investment Bank AB.

He is a Medical Doctor holding a PhD. from Karolinska Institutet in Stockholm and qualified as a Certified European Financial Analyst at Stockholm School of Economics.

Carl Harald will take responsibility for the Karolinska Development pharma project portfolio. Bringing with him a vast network of individuals with both management and operational skills, which will further strengthen the cost effective business model used by Karolinska Development.

About Karolinska Development

Karolinska Development is a Swedish investment company using a unique, highly cost effective model to commercialize internationally renowned life science innovations. Professionals in business development and management, supported by a network of experienced technical specialists, ensure fast and efficient development. This enables Karolinska Development to rapidly build value in high risk opportunities, through long term lead investor position from seed stage; developing the medical products of the future.

Karolinska Development's office is located at the Karolinska Institute Science Park, Sweden http://www.karolinskadevelopment.com
More about Karolinska Development: http://www.karolinskadevelopment.com

Contact: Conny Bogentoft, CEO

Tel: +46(0)8-524861-43

e-mail: info@karolinskadevelopment.com


'/>"/>
SOURCE Karolinska Development AB
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
4. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
5. Global Experts Explore Entire Spectrum of Aids Vaccine Development
6. Vical Names Andrew de Guttadauro Vice President, Corporate Development
7. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
8. SemBioSys updates Apo AI development program
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... SHANGHAI , Jan. 19, 2017 /PRNewswire -- ... medical device open-access capability and technology platform, today ... a leading biology focused preclinical drug discovery contract ... Biosciences will become a wholly-owned subsidiary of WuXi, ... core competences and providing greater services. The acquisition ...
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., today ... , Ph.D., as chief executive officer, as well ... Dr. Schmidt brings to ArmaGen more than 17 years ... and development of biotherapeutics and pharmaceuticals. ... the diverse experience and skillset necessary to lead ...
(Date:1/19/2017)... Minneapolis, Minnesota (PRWEB) , ... January 19, 2017 ... ... contract research organization with services spanning the full spectrum of drug and device ... clinical research services to pharma/device companies and clinicians, today announced Verified Clinical ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... essential device-to-computer interconnect using USB or PCI Express, announced the ZEM5310 USB 3.0 ... E FPGA into a compact business-card sized form factor suitable for prototyping, testing, ...
Breaking Biology Technology:
(Date:1/6/2017)... 2017  Delta ID Inc., a leader in consumer-grade ... automotive at CES® 2017. Delta ID has collaborated with ... the use of iris scanning as a secure, reliable ... in a car, and as a way to elevate ... Delta ID and Gentex will demonstrate (booth #7326 ...
(Date:12/22/2016)... Dec. 20, 2016  As part of its longstanding mission ... personal genetics company, recently released its latest children,s book, titled ... book focuses on the topics of inheritance and variation of ... (NGSS) taught in elementary school classrooms in the US. ... by illustrator Ariana Killoran , whose previous book with ...
(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
Breaking Biology News(10 mins):